title: Ondansentron and dexamethasone treatment with different dosing schedules (24 versus 32 mg) in patients with non-small-cell lung cancer under cisplatin-based chemotherapy: a randomized study.
abstract: The purpose of this study was to determine whether ondansentron given to patients with non-small-cell lung cancer (NSCLC) undergoing cisplatin-based chemotherapy, has better antiemetic activity administered every 6 or 8 h in controlling cisplatin-induced emesis. All patients had previously received 3 cycles of cisplatin-based chemotherapy at a dose of 100 mg/m(2). Ondansentron was given according to two schedules in group A (50 patients) at a dose of 8 mg in 100 ml normal saline over 10 min i.v. infusion, together with dexamethasone 8 mg before the infusion of cisplatin, continued with both drugs at the same dose and administration after 8 and 16 h; in group B (50 patients) both drugs were administered before the infusion of cisplatin, continued after 6, 12 and 18 h. During the next 3 days, patients continued with tablets of dexamethasone 4 mg and ondansentron 8 mg, group A every 8 h, and group B every 6 h. The only difference in terms of antiemetic response that was noticed between the two groups was the number of patients experiencing nausea which was found increased in group A (n = 32) in comparison to group B (n = 25) (p < 0.022). No difference was noticed in the number of vomiting episodes and retches or emesis control, during the 3-day evaluation period after cisplatin infusion or in side effects. In conclusion, the total dose of 24 mg ondansentron during the acute phase of emesis is as effective as the total dose of 32 mg.
authors.affiliation: Department of Pathophysiology, Oncology Unit, University of Athens School of Medicine, Laiko Hospital, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Tsavaris
authors.forename: C
authors.initials: C
authors.lastname: Kosmas
authors.forename: M
authors.initials: M
authors.lastname: Vadiaka
authors.forename: P
authors.initials: P
authors.lastname: Kanelopoulos
authors.forename: A
authors.initials: A
authors.lastname: Kontos
authors.forename: M
authors.initials: M
authors.lastname: Katsorida
authors.forename: A
authors.initials: A
authors.lastname: Agelopoulou
authors.forename: N
authors.initials: N
authors.lastname: Vrizidis
authors.forename: M
authors.initials: M
authors.lastname: Fotia
authors.forename: K
authors.initials: K
authors.lastname: Papoutsis
authors.forename: C
authors.initials: C
authors.lastname: Koufos
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000008:administration & dosage*; D014840:Vomiting, Anticipatory / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D017294:Ondansetron; D003907:Dexamethasone; D002945:Cisplatin